Camp4 Therapeutics Corp
Cambridge, United States · Biopharma, Biotechnology, Health Care
At CAMP4, we are pioneering a novel approach to programmable therapeutics. We combine a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality. Our RNA Actuating Platform’s proprietary insights enable us to harness the power of RNA to upregulate the expression of genes and unlock the potential to create treatments for hundreds of dis
Key facts
- Headquarters
- Cambridge, United States
- Employees
- Unknown
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (CAMP)
- Website
- https://www.camp4tx.com
- Company page
Recent activity at Camp4 Therapeutics Corp
- : CAMP4 Therapeutics Enters Research Collaboration Agreement with GSK (date Fundz recorded it)
- : SEC 8-K (7.01): On September 28, 2026, CAMP4 Therapeutics Corporation held an Analyst Day meeting to discuss its planned Phase 1/2 ASCEND clinical trial of CMP-002, aimed at treating SYNGAP1-related disorder. During this meeting, the Company presented updates on its product pipeline and shared a corporate presentation, which is available on their website. The presentation materials were also filed as Exhibits 99.1 and 99.2 with this 8-K filing, providing detailed insights into their ongoing clinical trials and development strategy, potentially impacting investor perceptions and market performance.
- : SEC 8-K (1.01): CAMP4 Therapeutics Corporation entered into an amendment to its existing Securities Purchase Agreement on August 3, 2026, with certain accredited investors. The amendment updates provisions related to the mechanics of the second closing of a private placement transaction. The initial closing had previously occurred on September 11, 2025, where the company sold 26,681,053 shares of common stock at a price of $1.53 per share, resulting in about $50.1 million in gross proceeds. This amendment follows an earlier announcement in July 2026 regarding clearance to initiate a clinical trial for its investigational product CMP-002, indicating important progress in the company's strategic initiatives.
- : SEC 8-K (8.01): On July 27, 2026, CAMP4 Therapeutics Corporation announced it received clearance from Australia’s Therapeutic Goods Administration and the local Human Research Ethics Committee to initiate a Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder. This clearance allowed the company to achieve the CTA Milestone, fulfilling significant terms in the previously disclosed Securities Purchase Agreement dated September 9, 2025. The company is now in a position to receive up to approximately $50.1 million in gross proceeds from the Second Closing, which is set to occur on or around August 3, 2026, pending customary conditions and investor participation. This milestone represents a strategic advancement in their clinical initiatives, potentially impacting their funding and operational capabilities moving forward.
- : SEC 8-K (5.02): On June 10, 2026, CAMP4 Therapeutics Corporation held its Annual Meeting where stockholders approved an amendment to the 2024 Equity Incentive Plan, specifically modifying the evergreen provision to include outstanding pre-funded warrants in the calculation of shares for annual increases. Concurrently, the Board approved the 2026 Inducement Plan, allowing the issuance of up to 500,000 stock options and other awards as incentives for new or rehired employees without seeking stockholder approval. These amendments and the introduction of the new plan reflect strategic measures to enhance employee compensation and retention in light of the company's growth initiatives.
- : SEC 8-K (7.01): On May 14, 2026, CAMP4 Therapeutics Corporation issued a press release titled 'CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder.' This disclosure aims to inform investors about newly obtained preclinical data which could influence the company's strategic position within the biotech sector. Additionally, the company updated its corporate slide presentation on the same date, enhancing transparency regarding its current research developments. The event date of May 14, 2026, and these materials are intended to provide timely and relevant information to stakeholders.
- : SEC 8-K (5.02):
- : SEC 8-K (2.01):
- : SEC 8-K (7.01): On January 9, 2026, CAMP4 Therapeutics Corporation updated its corporate presentation for the investment community. This update includes slides and presentations that summarize the company's business. The updated presentation is accessible in the 'Investors' section of the Company’s website and is also included as Exhibit 99.1 in this Form 8-K. This disclosure aims to keep investors informed about the strategic direction and recent developments at the Company. The information is not considered 'filed' under the Exchange Act and is intended for informational purposes only.
- : SEC 8-K (1.01): On December 22, 2025, CAMP4 Therapeutics Corporation and ARE-MA Region No. 59, LLC entered into the First Amendment to the Lease Agreement for approximately 30,760 square feet of laboratory and office space located at One Kendall Square, Cambridge, Massachusetts. The amendment accelerates the termination of the Cambridge Lease, originally set to expire on June 30, 2027, to a date 30 days after the Commencement Date of a new Watertown Lease with ARE-MA Region No. 75, LLC for roughly 44,000 square feet in Watertown, MA. The Watertown Lease, effective on the delivery of the premises, has an annual base rent of $40.00 per square foot with potential increases. The Company will pay a Lease Modification Fee of approximately $2.1 million to ARE 59, structured in monthly increments. The filing reflects a strategic move to consolidate operations and manage leasing costs, with base rent abatement terms specified contingent on default conditions.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Camp4 Therapeutics Corp funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2022 | Series B | $100.0M |
| Jun 2021 | Funding Round | $45.0M |
| Mar 2021 | Venture | $15.0M |
| Sep 2018 | Venture | $34.1M |
Leadership
- JOSH MANDEL-BREHM, Executive Officer, Director
- STEVE HOLTZMAN, Director
- JORGE CONDE, Director
- MICHAEL HIGGINS, Director
- AMIR NASHAT, Director
- PAULA RAGAN, Director
- RICHARD YOUNG, Director
- SHAAN GANDHI, Director
- ANDY SCHWAB, Director
- RAVI THADHANI, Director
Verified email and direct lines for Camp4 Therapeutics Corp’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Camp4 Therapeutics Corp files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to Camp4 Therapeutics Corp
- AnHeart Therapeutics · Biopharma, Biotechnology, Health Care, Science And Engineering, Therapeutics
- Theriva Biologics · Biopharma, Biotechnology, Health Care, Science And Engineering, Therapeutics
- Abivax · Biopharma, Biotechnology, Health Care, Therapeutics
- Apimeds Pharmaceuticals US · Biopharma, Biotechnology, Health Care, Therapeutics
- AbSci Corp · Biopharma, Biotechnology, Health Care, Therapeutics
About Camp4 Therapeutics Corp: questions and answers
What does Camp4 Therapeutics Corp do?
At CAMP4, we are pioneering a novel approach to programmable therapeutics. We combine a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality. Our RNA Actuating Platform’s proprietary insights enable us to harness the power of RNA to upregulate the expression of genes and unlock the potential to create treatments for hundreds of dis
Where is Camp4 Therapeutics Corp headquartered?
Camp4 Therapeutics Corp is headquartered in Cambridge, United States.
Has Camp4 Therapeutics Corp raised funding?
Yes. Fundz has recorded 4 funding events for Camp4 Therapeutics Corp. The most recent, Series B of $100.0M, was in Jul 2022.
What is the latest news on Camp4 Therapeutics Corp?
On Dec 18, 2025, CAMP4 Therapeutics Enters Research Collaboration Agreement with GSK
Is Camp4 Therapeutics Corp a public company?
Yes. Camp4 Therapeutics Corp is publicly traded under the ticker CAMP.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy